Acta Neuropathologica

, Volume 128, Issue 5, pp 639–650 | Cite as

Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

  • Min Shi
  • Changqin Liu
  • Travis J. Cook
  • Kristin M. Bullock
  • Yanchun Zhao
  • Carmen Ginghina
  • Yanfei Li
  • Patrick Aro
  • Romel Dator
  • Chunmei He
  • Michael J. Hipp
  • Cyrus P. Zabetian
  • Elaine R. Peskind
  • Shu-Ching Hu
  • Joseph F. Quinn
  • Douglas R. Galasko
  • William A. Banks
  • Jing ZhangEmail author
Original Paper


Extracellular α-synuclein is important in the pathogenesis of Parkinson’s disease (PD) and also as a potential biomarker when tested in the cerebrospinal fluid (CSF). The performance of blood plasma or serum α-synuclein as a biomarker has been found to be inconsistent and generally ineffective, largely due to the contribution of peripherally derived α-synuclein. In this study, we discovered, via an intracerebroventricular injection of radiolabeled α-synuclein into mouse brain, that CSF α-synuclein was readily transported to blood, with a small portion being contained in exosomes that are relatively specific to the central nervous system (CNS). Consequently, we developed a technique to evaluate the levels of α-synuclein in these exosomes in individual plasma samples. When applied to a large cohort of clinical samples (267 PD, 215 controls), we found that in contrast to CSF α-synuclein concentrations, which are consistently reported to be lower in PD patients compared to controls, the levels of plasma exosomal α-synuclein were substantially higher in PD patients, suggesting an increased efflux of the protein to the peripheral blood of these patients. Furthermore, although no association was observed between plasma exosomal and CSF α-synuclein, a significant correlation between plasma exosomal α-synuclein and disease severity (r = 0.176, p = 0.004) was observed, and the diagnostic sensitivity and specificity achieved by plasma exosomal α-synuclein were comparable to those determined by CSF α-synuclein. Further studies are clearly needed to elucidate the mechanism involved in the transport of CNS α-synuclein to the periphery, which may lead to a more convenient and robust assessment of PD clinically.


Parkinson’s disease Exosome α-synuclein Biomarker Plasma 



We thank Drs. Honglian Li and Sangwoo Jung for their kind help on EM method development, and Dr. Ane Korff for her assistance in Western blot confirmation. We also deeply appreciate the patients and participants for their generous participation and donation of samples. This study was supported by generous grants from the National Institutes of Health (NIH) (U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221 to JZ, R01 NS065070 to CPZ, and P50 AG005131 to DRG), and partially by a pilot study award from the NIH-sponsored ADRC at the UW (P50 AG003156-30) and a National Institute of Neurological Disorders and Stroke/NIH award R21 NS085425 to MS. It was also supported in part by the University of Washington’s Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

401_2014_1314_MOESM1_ESM.pdf (197 kb)
Supplementary material 1 (PDF 197 kb)


  1. 1.
    Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AH (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 67(12):1464–1472PubMedCrossRefGoogle Scholar
  2. 2.
    Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 42(3):360–367PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341–345PubMedCrossRefGoogle Scholar
  4. 4.
    Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888(2):287–296PubMedCrossRefGoogle Scholar
  5. 5.
    Banks WA, Broadwell RD (1994) Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin, and albumin: pharmacokinetic and morphological assessments. J Neurochem 62(6):2404–2419PubMedCrossRefGoogle Scholar
  6. 6.
    Banks WA, Kumar VB, Farr SA, Nakaoke R, Robinson SM, Morley JE (2011) Impairments in brain-to-blood transport of amyloid-beta and reabsorption of cerebrospinal fluid in an animal model of Alzheimer’s disease are reversed by antisense directed against amyloid-beta protein precursor. J Alzheimers Dis 23(4):599–605PubMedGoogle Scholar
  7. 7.
    Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5(2):55–59PubMedCrossRefGoogle Scholar
  8. 8.
    Bartels AL (2011) Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des 17(26):2771–2777PubMedCrossRefGoogle Scholar
  9. 9.
    Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S, Sadoul R (2012) Emerging role of neuronal exosomes in the central nervous system. Front Physiol 3:145PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB (2013) Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis 3(2):205–214PubMedPubMedCentralGoogle Scholar
  11. 11.
    Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH (2009) Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35(3):385–398PubMedCrossRefGoogle Scholar
  12. 12.
    Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 7:42PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R (2011) Parkinson disease: the enteric nervous system spills its guts. Neurology 77(19):1761–1767PubMedCrossRefGoogle Scholar
  14. 14.
    Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood-brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant 16(3):285–299PubMedCrossRefGoogle Scholar
  15. 15.
    Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106(31):13010–13015PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 134(Pt 7):e178PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F (2010) Plasma alpha-synuclein in patients with Parkinson’s disease with and without treatment. Mov Disord 25(4):489–493PubMedCrossRefGoogle Scholar
  18. 18.
    El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D (2003) alpha-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 17(13):1945–1947PubMedGoogle Scholar
  19. 19.
    El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 20(3):419–425PubMedCrossRefGoogle Scholar
  20. 20.
    Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30(20):6838–6851PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA (2012) Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation 9:150PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R (2006) Exosomes are released by cultured cortical neurones. Mol Cell Neurosci 31(4):642–648PubMedCrossRefGoogle Scholar
  23. 23.
    Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DM, Allsop D (2013) A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson’s disease. Sci Rep 3:2540PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D, Allsop D (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB J 25(12):4127–4137PubMedCrossRefGoogle Scholar
  25. 25.
    Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Greitz D, Greitz T, Hindmarsh T (1997) A new view on the CSF-circulation with the potential for pharmacological treatment of childhood hydrocephalus. Acta Paediatr 86(2):125–132PubMedCrossRefGoogle Scholar
  27. 27.
    Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Hakan W, Decraemer H, Nagga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69(11):1445–1452PubMedCrossRefGoogle Scholar
  28. 28.
    Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10(3):378–384PubMedCrossRefGoogle Scholar
  29. 29.
    Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42(9):781–785PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P (2011) alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121(2):715–725PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(Pt 3):713–726PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, Hulett MD, Mathivanan S (2013) Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 13(22):3354–3364PubMedCrossRefGoogle Scholar
  33. 33.
    Kenwrick S, Watkins A, De Angelis E (2000) Neural cell recognition molecule L1: relating biological complexity to human disease mutations. Hum Mol Genet 9(6):879–886PubMedCrossRefGoogle Scholar
  34. 34.
    Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P (2012) L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 6(4):374–384PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL (2006) alpha-Synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 20(12):2000–2008PubMedCrossRefGoogle Scholar
  36. 36.
    Korff A, Liu C, Ginghina C, Shi M, Zhang J (2013) alpha-Synuclein in cerebrospinal fluid of Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis 36(4):679–688PubMedPubMedCentralGoogle Scholar
  37. 37.
    Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot B, Haase G, Goldberg Y, Sadoul R (2011) Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 46(2):409–418PubMedCrossRefGoogle Scholar
  38. 38.
    Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339(15):1044–1053PubMedCrossRefGoogle Scholar
  39. 39.
    Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm 113(10):1435–1439PubMedCrossRefGoogle Scholar
  40. 40.
    Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J (2011) Microvesicles as mediators of intercellular communication in cancer–the emerging science of cellular ‘debris’. Semin Immunopathol 33(5):455–467PubMedCrossRefGoogle Scholar
  41. 41.
    Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1):R48–R59PubMedCrossRefGoogle Scholar
  42. 42.
    Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, Culvenor JG, Horne MK (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease. Exp Neurol 204(2):583–588PubMedCrossRefGoogle Scholar
  43. 43.
    Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J (2012) DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2:954PubMedPubMedCentralGoogle Scholar
  44. 44.
    Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45(3):353–357PubMedCrossRefGoogle Scholar
  45. 45.
    MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7):966–968PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Magdalinou N, Lees AJ, Zetterberg H (2014) Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2013-307539 PubMedPubMedCentralGoogle Scholar
  47. 47.
    Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG (2014) alpha-Synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease: a systematic review. Acta Neurol Scand. doi: 10.1111/ane.12247 Google Scholar
  48. 48.
    Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67(11):1350–1356PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213(2):315–325PubMedCrossRefGoogle Scholar
  51. 51.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230–240PubMedCrossRefGoogle Scholar
  52. 52.
    Nagaraja TN, Patel P, Gorski M, Gorevic PD, Patlak CS, Fenstermacher JD (2005) In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res 2:5PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Nixon RA, Yang DS, Lee JH (2008) Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4(5):590–599PubMedCrossRefGoogle Scholar
  54. 54.
    Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21(20):8053–8061PubMedGoogle Scholar
  55. 55.
    Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047PubMedCrossRefGoogle Scholar
  56. 56.
    Record M, Subra C, Silvente-Poirot S, Poirot M (2011) Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 81(10):1171–1182PubMedCrossRefGoogle Scholar
  57. 57.
    Reed DJ, Woodbury DM (1963) Kinetics of movement of iodide, sucrose, inulin and radio-iodinated serum albumin in the central nervous system and cerebrospinal fluid of the rat. J Physiol 169:816–850PubMedPubMedCentralGoogle Scholar
  58. 58.
    Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein DS, Zhang J (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69(3):570–580PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 480(1):78–82PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Shults CW (2006) Lewy bodies. Proc Natl Acad Sci USA 103(6):1661–1668PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41(12):1308–1312PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Simpson R, Mathivanan S (2012) Extracellular microvesicles: the need for internationally recognised nomenclature and stringent purification criteria. J Proteomics Bioinform 5:2CrossRefGoogle Scholar
  63. 63.
    Simpson RJ, Jensen SS, Lim JW (2008) Proteomic profiling of exosomes: current perspectives. Proteomics 8(19):4083–4099PubMedCrossRefGoogle Scholar
  64. 64.
    Simpson RJ, Kalra H, Mathivanan S (2012) ExoCarta as a resource for exosomal research. J Extracell Vesicles 1:18374Google Scholar
  65. 65.
    Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, Simpson RJ (2012) Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 56(2):293–304PubMedCrossRefGoogle Scholar
  67. 67.
    Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 349(1):162–166PubMedCrossRefGoogle Scholar
  68. 68.
    Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J (2013) CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer’s disease. Acta Neuropathol 126(5):683–697PubMedCrossRefGoogle Scholar
  69. 69.
    Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson’s disease. Lancet Neurol 5(1):75–86PubMedCrossRefGoogle Scholar
  70. 70.
    Wang N, Gibbons CH, Lafo J, Freeman R (2013) alpha-Synuclein in cutaneous autonomic nerves. Neurology 81(18):1604–1610PubMedCrossRefGoogle Scholar
  71. 71.
    Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F, Hansson O, Nielsen HM (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8(1):e53250PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Winkler J, Ehret R, Buttner T, Dillmann U, Fogel W, Sabolek M, Winkelmann J, Kassubek J (2011) Parkinson’s disease risk score: moving to a premotor diagnosis. J Neurol 258(Suppl 2):S311–S315PubMedCrossRefGoogle Scholar
  73. 73.
    Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19(6):533–542PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Min Shi
    • 1
  • Changqin Liu
    • 2
  • Travis J. Cook
    • 3
  • Kristin M. Bullock
    • 4
    • 5
  • Yanchun Zhao
    • 1
  • Carmen Ginghina
    • 1
  • Yanfei Li
    • 3
  • Patrick Aro
    • 1
  • Romel Dator
    • 1
  • Chunmei He
    • 6
  • Michael J. Hipp
    • 1
  • Cyrus P. Zabetian
    • 4
    • 7
    • 8
  • Elaine R. Peskind
    • 9
    • 10
  • Shu-Ching Hu
    • 4
    • 7
    • 8
  • Joseph F. Quinn
    • 11
  • Douglas R. Galasko
    • 12
  • William A. Banks
    • 4
    • 5
  • Jing Zhang
    • 1
    Email author
  1. 1.Department of PathologyUniversity of Washington School of MedicineSeattleUSA
  2. 2.Department of Endocrinology and DiabetesThe First Affiliated Hospital of Xiamen UniversityXiamenChina
  3. 3.Department of Environmental and Occupational Health SciencesUniversity of Washington School of Public HealthSeattleUSA
  4. 4.Geriatric Research, Education, and Clinical CenterVeterans Affairs Puget Sound Health Care SystemSeattleUSA
  5. 5.Division of Gerontology and Geriatric Medicine, Department of MedicineUniversity of Washington School of MedicineSeattleUSA
  6. 6.Department of Endocrinology and Diabetes, Xiamen Diabetes InstituteThe First Affiliated Hospital of Xiamen UniversityXiamenChina
  7. 7.Parkinson’s Disease Research, Education, and Clinical CenterVeterans Affairs Puget Sound Health Care SystemSeattleUSA
  8. 8.Department of NeurologyUniversity of Washington School of MedicineSeattleUSA
  9. 9.Department of Psychiatry and Behavioral SciencesUniversity of Washington School of MedicineSeattleUSA
  10. 10.Mental Illness Research, Education, and Clinical CenterVeterans Affairs Puget Sound Health Care SystemSeattleUSA
  11. 11.Department of NeurologyOregon Health and Science UniversityPortlandUSA
  12. 12.Department of NeurosciencesUniversity of California at San DiegoLa JollaUSA

Personalised recommendations